David Aggen, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on LinkedIn:
“A major challenge for patients on Enfortumab Vedotin for prolonged periods is mitigating neuropathy.
At Memorial Sloan Kettering Cancer Center we are actively investigating the use of a novel MMAE binder to prevent neuropathy for patients with metastatic urothelial cancer in collaboration with Jacqueline Brown and Emory Healthcare.”
You can alaos read:
10 Bladder and Urothelial Cancer Trials to Watch at ESMO 2026
